Lupin’s Mandideep Unit-2 Facility Completes USFDA Inspection With Zero Observations
Indian pharma major Lupin on Saturday said that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
“We are pleased to announce that the U.S. FDA inspection of our Mandideep Unit-2 facility concluded with no observations. This further reaffirms our commitment to superior quality and compliance standards,” said Nilesh Gupta, Managing Director, Lupin.
On Monday the company's stock was trading 0.66 per cent higher at Rs 1083.55 per scrip as of 14:48 IST on BSE.
